Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma (BRiM)

NCT02257242 PHASE1 COMPLETED Results posted

This study evaluates addition of Vincristine Sulfate Liposome Injection (Marqibo®) to the standard regimen of Bendamustine and Rituximab in adult patients with indolent B-cell lymphoma. This is a dose-escalation study.

Details

Lead sponsor	Brown University
Phase	PHASE1
Status	COMPLETED
Enrolment	11
Start date	Wed May 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Nov 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Lymphoma, Non-Hodgkin
• Lymphoma, Follicular
• Lymphoma, Mantle-Cell
• Lymphoma, Small-Cell
• Waldenstrom Macroglobulinemia
• Lymphoma, B-Cell, Marginal Zone

Interventions

• Rituximab
• Bendamustine
• Vincristine sulfate liposome injection

Countries

United States